Double blind placebo controlled trial of short term transdermal scopolamine on heart rate variability in patients with chronic heart failure

Heart

Volumn 76, Issue 2, 1996, Pages 137-143

  Venkatesh, Govindarajan ^a   Fallen, Ernest L ^a,b   Kamath, Markad V ^a   Connolly, Stuart ^a   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Left ventricular dysfunction; Power spectrum; Scopolamine; Time domain analysis

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; SCOPOLAMINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; FEMALE; HEART FAILURE; HEART RATE; HOLTER MONITORING; HUMAN; MALE; PRIORITY JOURNAL; STANDING; SYMPATHETIC TONE; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0029758893     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.76.2.137     Document Type: Article

References (29)

1. Packer M. Neurohumoral interactions and adaptations in congestive heart failure. Circulation 1988;77:721-30.
2. Eckberg DL, Drabinsky M, Braunwald E. Detective cardiac parasympathetic control in patients with heart disease. N Eng J Med 1971;285:877-83.
3. Saul PJ, Arai Y, Berger RD, Lilly LS, Colucci WS, Cohen RJ. Assessment of autonomic regulation in chronic congestive heart failure by heart rate spectral analysis. Am J Cardiol 1988;61:1292-9.
4. Schwartz P, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Circulation 1992;85 suppl II:77-91.
5. Kleiger RE, Miller JP, Bigger JT (Jr), Moss AJ and the Multicentre post-infarction research group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-62.
6. Nolan J, Flapan AD, Capewell S, MacDonald TM, Neilson JMM, Ewing DJ. Decreased cardiac parasympathetic activity in chronic heart failure and its relation to left ventricular function. Br Heart J 1992;67:482-5.
7. Malik M, Camm AJ. Heart rate variability. Clin Cardiol 1990;13:570-6.
8. Coats AJS, Adamopoulos S, Radaelli A, McCance A, Meyer TE, Bernardi L, et al. Controlled trial of physical training in chronic heart failure: exercise performance, hemodynamics, ventilation and autonomic function. Circulation 1992;85:2119-31.
9. Cook JR, Bigger JT, Kleiger RE, Steinman RC, Rolnitzky LM, Fleiss JL. Effect of atenolol and diltiazem on heart rate variability in normal persons. J Am Coll Cardiol 1991;17:480.
10. Pagani M, Lobardi F, Guzetti S, Rimoldi O, Furlan R, Pissinelli P, et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympathovagal interaction in man and conscious dog. Circ Res 1986;59:178-93.
11. Kamath MV, Upton ARM, Tallala A, Fallen EL. Neurocardiac responses to vagoafferent electrical stimulation in humans. PACE 1992;15:1581-7.
12. Weise F, Baltrusch K, Heydenreich F. Effect of low dose atropine on heart rate fluctuations during orthostatic load: a spectral analysis. J Auton Nerv Syst 1989;26: 223-30.
13. Katona PG, Lipson D, Dauchot PJ. Opposing central and peripheral effects of atropine on parasympathetic cardiac control. Am J Physiol 1977;232:H146-51.
14. Dibner-Dunlap ME, Eckberg DJ, Magid NM, Cirtron-Trevino NM. The long-term increase of baseline and reflexly augmented levels of human vagal-cardiac nervous activity induced by scopolamine. Circulation 1985;71: 797-804.
15. Vybiral T, Bryg RJ, Maddens ME, Bhassin SS, Chronin S, Boden WE, et al. Effects of transdermal scopolamine on heart rate variability in normal subjects. Am J Cardiol 1990;65:604-8.
16. Casadei B, Pipilis A, Sessa F, Conway J, Sleight P. Low doses of scopolamine increase cardiac vagal tone in the acute phase of myocardial infarction. Circulation 1993; 88:353-7.
17. Pedretti R, Colombo E, Sary Braga S, Caru B. Influence of transdermal scopolamine on cardiac sympathovagal interaction after acute myocardial infarction. Am J Cardiol 1993;72:384-92.
18. La Rovere MT, Mortara A, Pantalo P, Maestri R, Cobelli F, Tavazzi L. Scopolamine improves autonomic balance in advanced congestive heart failure. Circulation 1994; 90:838-43.
19. Malik M, Farrell T, Cripps T, Camm AJ. Heart rate variability in relation to prognosis after myocardial infarction: Selection of optimal processing techniques. Eur Heart J 1989;10:1060-74.
20. Kay S, Marple SL. Spectrum analysis: a modern perspective. Proc IEEE 1981;69:1380-8.
21. Fallen EL, Kamath MV, Ghista DA. Power spectrum analysis of heart rate variability: a non-invasive test of integrated neurocardiac function. Clin Invest Med 1988; 11:331-40.
22. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rates reliability. Psychol Bull 1979;86:420-8.
23. Bianchi A, Bontempi B, Cerutti S, Gianogho P, Comi G, Natali Sora MG. Spectral analysis of heart rate variability signal and respiration in diabetic subjects. Med Biol Eng Comput 1990;28:205-11.
24. Raczkokwska M, Eckberg DL, Ebert TJ. Muscarinic cholinergic receptors modulate vagal cardiac responses in man. J Auton Nerv Syst 1983;7:271.
25. Loffelholz K, Pappano AJ. The parasympathetic neuroeffector junction of the heart. Pharm Rev 1985;37:1-24.
26. Levy MN. Cardiac sympathetic Fedn Proc 1984;43: 4598-2602.
27. Packer M, Carver JR, Rodcheffer R, Ivanhoe RJ, Dibianco R, et al for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe congestive heart failure. N Eng J Med 1991;325:1468-75.
28. Pedretti RFE, Colombo FE, Braga SS, Ballardini L, Caru B. Effects of oral pirenzepine on heart rate variability and baroreceptor reflex sensitivity after acute myocardial infarction. J Am Coll Cardiol 1995;25: 915-21.
29. Hull SS, Vanoli E, Adamson PB, DeFarran GM, Foreman RD, Schwartz PJ. Do increases in markers of vagal activity imply protection from sudden death? The case of scopolamine. Circulation 1995;91:2516-9.